New drug AWT020 takes on advanced solid tumors

NCT ID NCT06839105

Recruiting now Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants must have tried standard treatments without success or have no standard options available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AWT020
What this could lead to: If safe and effective, AWT020 could become a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong: This is an early phase 1 trial with a small number of participants, so the drug may not prove effective or may cause unexpected side effects. Success in this phase does not guarantee later approval.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal neoplasm hepatocellular carcinoma melanoma non-small cell lung carcinoma nonpapillary renal cell carcinoma rectum adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER, COLORECTAL CANCER, RENAL CELL CARCINOMA, MELANOMA AND OTHER SOLID TUMOR

Contacts and locations

Locations

First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330006, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350014, China
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150081, China
Hubei Cancer Hospital
RECRUITING

Wuhan, Hubei, 430079, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410000, China
Liaoning Cancer Hospital & Institute
NOT_YET_RECRUITING

Shenyang, Liaoning, 110042, China
Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of Henan University of Science & Technology
NOT_YET_RECRUITING

Luoyang, Henan, 471099, China
The First Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, 400042, China
The First Hospital of Jilin University
NOT_YET_RECRUITING

Changchun, Jilin, China
Yunnan Cancer Hospital
NOT_YET_RECRUITING

Kunming, Yunnan, 650118, China
Zhejiang Cancer Hospital
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.